Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo
Authors:
- Émile BreaultÉBÉmile Breault
- Jolien De NeveJNJolien De Neve
- Amirmohammad RanjbaranARAmirmohammad Ranjbaran
- Alexandre TremblayATAlexandre Tremblay
- Ines RobberechtsIRInes Robberechts
- Frédérique LussierFLFrédérique Lussier
- Félix BélairFBFélix Bélair
- Victoria TremblayVTVictoria Tremblay
- Brian J. HolleranBHBrian J. Holleran
- Isabelle BrochuIBIsabelle Brochu
- Nicolò BisiNBNicolò Bisi
- Jérôme CôtéJCJérôme Côté
Open Access
- 11 May 2026
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119488
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (FDN-148413)
- Santé
- Natural Sciences and Engineering Research Council of Canada
- Vrije Universiteit Brussel (OZR3939)
- Vrije Universiteit Brussel (SRP50 SRP95)
- Vrije Universiteit Brussel (OZR3584)
- Fonds Wetenschappelijk Onderzoek (1SB0422N)
This publication has 105 references indexed in Scilit:
- Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy GrailCNS Drugs, 2025
- Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free AnalgesicsAngewandte Chemie International Edition, 2024
- The Delta Opioid Receptor in Pain Control2017
- Twin and Triplet Drugs in Opioid Research2010
- Tail-flick test I: Impact of a suprathreshold exposure to radiant heat on pain reactivity in ratsPhysiology & Behavior, 1995
- Morphine-induced straub tail response: Mediated by central μ2-opioid receptorEuropean Journal of Pharmacology, 1994
- Microinjection of neurotensin into the ventral tegmental area produces hypothermia: Evaluation of dopaminergic mediationBrain Research, 1985
- Release of histamine and adrenaline following intravenous administration of neurotensinLife Sciences, 1983
- The hypotensive effect of centrally administered neutrotensin in ratsEuropean Journal of Pharmacology, 1981
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973